Join forces with us and innovate

Gastrointestinal.

GI diseases partner programs

Gubra gastrointestinal diseases partner programs

GI program #1: GLP1/GLP2 co-agonist for Short Bowel Disease
Short Bowel Syndrome (SBS) is an orphan disease on the rise with significant unmet medical needs. Gubra has developed a library of potent dual GLP1/GLP2 agonists and a lead molecule has been selected and tested in a number of in vivo and in vitro models

  • Lead molecule short-acting single peptide for ready-to-use injection
  • This new biological concept combines stimulation of intestinal growth and the iliac brake
  • Library of +150 rational design peptides and established SAR
  • Acute and chronic PoC of dual activity in vivo, PK properties and in vitro potency established
  • Currently at lead optimization phase and ready for partnering

GI program #2: Gut peptide target discovery

  • Target discovery focusing on targets involved in celiac disease, ulcerative colitis and IBD
  • Program ready for partnering

Other GI programs – If you have other ideas, please let us know.

We have several years of experience driving partner programs together with world leading companies. We engage in both target discovery and peptide drug development collaborations. All necessary disciplines are in-house (in vivo pharmacology, histology, peptide synthesis, assay development, RNA sequencing and bioinformatics etc.) enabling short discovery and development loops and rapid project progression.

Get in touch

Get in touch if you are interested in discussing how to engage with Gubra on a partner program.

Trine Nygaard Hamann

Business Development
tnh@gubra.dk
+45 5124 9818

Get in touch

Contact us

Drug development framework

Our drug development projects follow this high-level framework:

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

info@gubra.dk
+45 3152 ­2650